Metabolomic Insights from IV Ketamine in TRD: Bio-K/NNDC US Multicenter Trial

Multicenter Bio-K/NNDC Trial Finds Broad Metabolic Effects of Ketamine in TRD

The Bio-K/NNDC trial, registered as NCT03156504, is a multicenter, open-label study that investigated the metabolomic effects of intravenous (IV) racemic ketamine in adults with treatment-resistant major depressive disorder (TRD). Conducted across multiple US academic sites, the trial enrolled 69 adults who received three IV infusions of ketamine (0.5 mg/kg), with primary outcomes measured by the Montgomery–Åsberg Depression Rating Scale (MADRS). The study found a mean MADRS improvement from 27.8 ± 5.8 to 11.1 ± 9.1 after the third infusion, with 54% of participants achieving remission (MADRS ≤9) at 24 hours post–third infusion. These results confirm ketamine's rapid antidepressant effect in a real-world, treatment-resistant population.

Mechanistic Findings: Metabolomic Shifts and Neurotransmitter Modulation

Metabolomic profiling using the Biocrates MxP® Q500 kit (>600 metabolites) revealed that ketamine administration induced widespread metabolic changes, including increased levels of acylcarnitines, cortisol, amino acids (notably glutamine, glycine, and branched-chain amino acids), and biogenic amines such as gamma-aminobutyric acid (GABA) and putrescine after the first infusion. Medium-chain acylcarnitines and glutamate levels decreased. By the third infusion, elevations in C16 acylcarnitine, serotonin, and GABA persisted, while cortisol levels normalized. These findings suggest that ketamine's antidepressant effects are accompanied by shifts in mitochondrial function, neurotransmitter synthesis, and neuroendocrine signaling—supporting hypotheses that its mechanism extends beyond NMDA receptor antagonism to broader bioenergetic and neurochemical pathways.

Importantly, while remitters exhibited greater increases in GABA synthesis, no single metabolite or metabolic change robustly predicted clinical response after correcting for multiple comparisons. This underscores the complexity of ketamine's action and the challenge of identifying reliable biomarkers for antidepressant response in heterogeneous TRD populations.

Policy, Clinical, and Research Implications: No Immediate Biomarker Utility

The Bio-K/NNDC trial's results deepen our mechanistic understanding of ketamine in TRD but do not yet translate into actionable clinical decision tools or regulatory changes. The absence of validated metabolomic predictors means that clinicians cannot currently use these data to select patients or tailor dosing based on metabolic profiles. For regulators such as the US Food and Drug Administration (FDA), these findings do not alter the risk-benefit calculus or labeling for ketamine in depression, as they provide correlative, not causative, evidence.

For researchers, the study highlights the need for larger, possibly placebo-controlled trials with longitudinal follow-up and more granular metabolic sampling. The failure to identify predictive biomarkers in this well-powered, multicenter setting suggests that future efforts may need to focus on multi-omic integration (combining genomics, proteomics, and metabolomics), machine learning approaches, or stratification by clinical subgroups. An underappreciated implication is that metabolic signatures may reflect state changes associated with symptom improvement rather than trait markers that can guide pre-treatment decision-making—a distinction critical for future biomarker discovery efforts.

Risks, Unknowns, and Cautions in Translating Metabolomic Data

No metabolomic signature identified in this trial can currently be used to guide clinical care, and the broad metabolic changes observed raise questions about off-target effects and long-term safety. The open-label design, while pragmatic, limits causal inference regarding specific metabolic pathways and their role in antidepressant response. Additionally, the diversity of metabolic changes—spanning mitochondrial, neurotransmitter, and neuroendocrine pathways—complicates efforts to isolate a single mechanism or risk factor.

There is also the risk of overinterpreting correlational data: while GABA increases were more pronounced in remitters, this association did not survive correction for multiple testing, and could reflect downstream effects of symptom improvement rather than a mechanistic driver. The lack of placebo control means some metabolic shifts could be non-specific or related to repeated IV infusions rather than ketamine itself.

Looking Ahead: Next Steps for Translational and Regulatory Science

Future research should prioritize placebo-controlled, multi-omic studies with larger and more diverse TRD populations, aiming to disentangle state- versus trait-related metabolic changes and to identify composite biomarkers that could inform patient selection or risk stratification. For clinicians, the key takeaway is that while ketamine remains a promising intervention for TRD, metabolomic profiling is not yet ready for routine use in guiding care. For policy makers and regulators, the study reinforces the need for robust, replicable biomarker validation before integrating metabolomic data into approval or reimbursement frameworks.

One non-obvious implication is that the metabolic complexity observed here may explain the heterogeneity in clinical response to ketamine seen in real-world settings, and that future biomarker discovery efforts may need to account for dynamic, treatment-induced changes rather than static baseline measures. As the field moves forward, integrating metabolomic data with clinical, genetic, and neuroimaging information may be necessary to unlock precision psychiatry approaches for TRD.

How we research / reviewed by: Dr. Alex R. McGuire, MD, PhD (psychiatrist, clinical trialist). Reviewed on 2026-09-10. Sources: Bio-K/NNDC trial registry (NCT03156504), original publication (OpenAlex W7210277337).